Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy

Increasing the T-cell immune response to Mycobacterium tuberculosis with an anti-programmed cell death 1 (anti-PD-1) antibody may ultimately have detrimental effects. We present the case of a patient with advanced non-small cell lung cancer who developed active tuberculosis (TB) after initial treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Shuji, Usui, Ryou, Nakahara, Yoshiro, Kondo, Tetsuro, Kato, Terufumi, Saito, Haruhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222114/
https://www.ncbi.nlm.nih.gov/pubmed/33390489
http://dx.doi.org/10.2169/internalmedicine.6002-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222114/
https://www.ncbi.nlm.nih.gov/pubmed/33390489
http://dx.doi.org/10.2169/internalmedicine.6002-20

Ejemplares similares